The Nottingham Prognostic Index Plus (NPI+) is an award winning decision making tool for clinicians to offer personalised medicine to all female patients with breast cancer. NPI+ builds considerably upon the original NPI that was developed in Nottingham in the early 1980s. NPI+ includes ground breaking functionality by predicting both clinical outcomes (survival) and by aiding customised therapeutics. NPI+ can be used for all female breast cancer patients, not just those who are oestrogen receptor positive.
A final draft version of this year’s FP7 Health Work Programme is due to be available at the end of the month. (This year’s call is known as the 2011 call as projects are due to start in 2011). The total budget is predicted to be in the region of EUR 640 million, and the [...]